Filters
In Asian patients with esophageal squamous cell carcinoma (ESCC), adding the TIGIT inhibitor tiragolumab and PD-L1 inhibitor atezolizumab to chemotherapy improved all outcomes in the phase III SKYSCRAPER-08 trial.
New drug applications approved by US FDA as of 01-15 February 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Exposure to potassium-competitive acid blockers (PCABs) may heighten the risk of developing gastric cancer after successful treatment for Helicobacter pylori infection, according to a study.
Use of high-dose oxytocin postpartum appears to result in reduced rates of postpartum haemorrhage (PPH) when compared with traditional doses, as shown in a study presented at SMFM 2024.
Testosterone treatment does not help lower the incidence of clinical fractures in middle-aged and older men with hypogonadism, according to a study.
Use of topical mupirocin prophylaxis is feasible and has an acceptable safety profile for the long-term prevention of indwelling pleural catheter (IPC)- or indwelling peritoneal catheter (IPeC)-related infections, results of a pilot study have shown.
Treatment with semaglutide induces weight loss in Asians with overweight or obesity, regardless of the presence of type 2 diabetes, according to the phase IIIa STEP 7 study.
Early treatment with tumour necrosis factor (TNF) inhibitors lowers the risk of perianal fistulizing complications (PFCs) in children and teens compared with no immunosuppression or immunomodulators without TNF inhibitors in a post-hoc analysis of a prospective observational study.
Positioning patients with large vessel occlusion (LVO) stroke flat on the bed prior to thrombectomy helps improve neurologic outcomes in the randomized controlled ZODIAC* trial.
A recent study has reported the prevalence of serious infection (SI) among patients with systemic lupus erythematosus (SLE) following treatment with rituximab (RTX).
